Literature DB >> 22842224

The optimal timing for imaging brain tumours and other brain lesions with 18F-labelled fluoromethylcholine: a dynamic positron emission tomography study.

Koen Mertens1, Julie Bolcaen, Hamphrey Ham, Karel Deblaere, Caroline Van den Broecke, Tom Boterberg, Filip De Vos, Ingeborg Goethals.   

Abstract

PURPOSE: To determine the optimal timing for imaging brain tumours and other brain lesions with 18F-labelled fluoromethylcholine (18F-FCho) PET.
MATERIALS AND METHODS: Dynamic PET imaging with 18F-FCho (acquisition time of 28 min) was performed in 24 patients with space-occupying lesions in the brain. On the coregistered PET and MRI, lesion-to-normal tissue uptake ratios (LNRs) were calculated. Time-activity curves (TACs) were generated on the basis of the LNRs. Changes in LNR over time were calculated on the basis of the linear part of the TAC (last 22 min of the acquisition).
RESULTS: TACs for 18F-FCho in gliomas of different grading showed that, after a rapid uptake phase, the mean increase in LNR was 1.07 ± 0.93 for glioblastomas, -0.52 ± 1.56 for anaplastic astrocytomas, 0.04 ± 0.13 for grade 2 oligoastrocytomas and 0.37 in a case of a pilocytic astrocytoma. The average increase in LNR was 0.46 for a brain metastasis, 0.41 ± 0.69 for radiation-induced mass lesions and 1.07 for a tumefactive demyelinating lesion. In contrast, TACs for 18F-FCho in meningiomas showed that, after a rapid uptake phase, the average change in LNR was -5.25 ± 4.19 for typical meningiomas and -3.04 in a case of a mixed angiomatous and clear cell meningioma.
CONCLUSION: On the basis of the TACs, PET imaging with 18F-FCho starting within minutes after the administration of the tracer is preferred for the detection of brain tumours and other brain lesions. If discrimination between meningioma and other brain tumours is of concern, both 'early' and 'late' PET imaging could be helpful.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22842224     DOI: 10.1097/MNM.0b013e328355b6f5

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Editorial commentary to "18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases" by Grkovski and colleagues.

Authors:  Pierre Lovinfosse; Selma Ben Mustapha; Nadia Withofs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06       Impact factor: 9.236

Review 2.  Molecular imaging of brain tumors with radiolabeled choline PET.

Authors:  Ferdinando Franco Calabria; Manlio Barbarisi; Vincenzo Gangemi; Giovanni Grillea; Giuseppe Lucio Cascini
Journal:  Neurosurg Rev       Date:  2016-05-26       Impact factor: 3.042

3.  ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility.

Authors:  Manuel Gómez-Río; Nathalie Testart Dardel; Alicia Santiago Chinchilla; Antonio Rodríguez-Fernández; Gonzalo Olivares Granados; Raquel Luque Caro; Mercedes Zurita Herrera; Clara E Chamorro Santos; Pablo Lardelli-Claret; José M Llamas-Elvira
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

Review 4.  Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma.

Authors:  Aurélie Moreau; Olivia Febvey; Thomas Mognetti; Didier Frappaz; David Kryza
Journal:  Front Oncol       Date:  2019-11-01       Impact factor: 6.244

Review 5.  Prediction of Meningioma WHO Grade Using PET Findings: A Systematic Review and Meta-Analysis.

Authors:  K Mariam Slot; Dagmar Verbaan; Dennis R Buis; Linda J Schoonmade; Bart N M Berckel; W Peter Vandertop
Journal:  J Neuroimaging       Date:  2020-11-02       Impact factor: 2.486

Review 6.  SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases.

Authors:  Barbara Palumbo; Tommaso Buresta; Susanna Nuvoli; Angela Spanu; Orazio Schillaci; Mario Luca Fravolini; Isabella Palumbo
Journal:  Int J Mol Sci       Date:  2014-06-03       Impact factor: 5.923

7.  Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer.

Authors:  Marina Hodolic; Virginie Huchet; Sona Balogova; Laure Michaud; Khaldoun Kerrou; Valérie Nataf; Marino Cimitan; Jure Fettich; Jean-Noël Talbot
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.